The Use of “Acellbia”—A Biosimilar of Rituximab in Systemic Sclerosis

IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
L. P. Ananyeva, L. A. Garzanova, O. V. Desinova, R. U. Shayakhmetova, M. N. Starovoitova, O. A. Koneva, O. B. Ovsyannikova, S. I. Glukhova, E. L. Nasonov
{"title":"The Use of “Acellbia”—A Biosimilar of Rituximab in Systemic Sclerosis","authors":"L. P. Ananyeva,&nbsp;L. A. Garzanova,&nbsp;O. V. Desinova,&nbsp;R. U. Shayakhmetova,&nbsp;M. N. Starovoitova,&nbsp;O. A. Koneva,&nbsp;O. B. Ovsyannikova,&nbsp;S. I. Glukhova,&nbsp;E. L. Nasonov","doi":"10.1134/S1607672924700844","DOIUrl":null,"url":null,"abstract":"<p>The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a disease-modifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One example is anti-B-cell therapy, in particular rituximab (RTX). Until now RTX does not have a registration for the treatment of SSc, but there is a large positive experience of its use, which is reflected in recent meta-analyses and clinical recommendations. Complicated and expensive methods for obtaining genetically engineered biological drugs (biologics) have contributed to the emergence of more accessible biosimilars, one of which is the RTX biosimilar, Acellbia (Biocad, Russian Federation). The ‘‘biosimilar’’ versions of RTX might reduce the cost of therapy and increase patients accessibility to this treatment option. The RTX biosimilar Acellbia (ACB) has received approval in Russian Federation in 2014 for all indications held by reference RTX (including rheumatoid arthritis and ANCA-associated vasculitis).</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Doklady Biochemistry and Biophysics","FirstCategoryId":"99","ListUrlMain":"https://link.springer.com/article/10.1134/S1607672924700844","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a disease-modifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One example is anti-B-cell therapy, in particular rituximab (RTX). Until now RTX does not have a registration for the treatment of SSc, but there is a large positive experience of its use, which is reflected in recent meta-analyses and clinical recommendations. Complicated and expensive methods for obtaining genetically engineered biological drugs (biologics) have contributed to the emergence of more accessible biosimilars, one of which is the RTX biosimilar, Acellbia (Biocad, Russian Federation). The ‘‘biosimilar’’ versions of RTX might reduce the cost of therapy and increase patients accessibility to this treatment option. The RTX biosimilar Acellbia (ACB) has received approval in Russian Federation in 2014 for all indications held by reference RTX (including rheumatoid arthritis and ANCA-associated vasculitis).

在系统性硬化症中使用 "Acellbia"--一种利妥昔单抗的生物仿制药。
现代疗法治疗系统性硬化症(SSc)的可能性仍然有限,因为大多数常用药物都没有改变病情的作用。这就促使人们研究有可能影响疾病基本病理过程的新方法。其中一个例子就是抗 B 细胞疗法,特别是利妥昔单抗(RTX)。到目前为止,利妥昔单抗还没有注册用于治疗 SSc,但使用该疗法已有大量积极的经验,这反映在最近的荟萃分析和临床建议中。获得基因工程生物药物(生物制剂)的方法复杂而昂贵,这促使出现了更容易获得的生物仿制药,RTX 生物仿制药 Acellbia(俄罗斯联邦 Biocad 公司)就是其中之一。RTX的 "生物仿制药 "可能会降低治疗成本,使患者更容易获得这种治疗选择。RTX生物仿制药Acellbia(ACB)已于2014年在俄罗斯联邦获得批准,可用于参考RTX的所有适应症(包括类风湿性关节炎和ANCA相关性血管炎)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Doklady Biochemistry and Biophysics
Doklady Biochemistry and Biophysics 生物-生化与分子生物学
CiteScore
1.60
自引率
12.50%
发文量
68
审稿时长
6-12 weeks
期刊介绍: Doklady Biochemistry and Biophysics is a journal consisting of English translations of articles published in Russian in biochemistry and biophysics sections of the Russian-language journal Doklady Akademii Nauk. The journal''s goal is to publish the most significant new research in biochemistry and biophysics carried out in Russia today or in collaboration with Russian authors. The journal accepts only articles in the Russian language that are submitted or recommended by acting Russian or foreign members of the Russian Academy of Sciences. The journal does not accept direct submissions in English.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信